Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBP-4888 in healthy female volunteers
NCT05881993Phase 1Completed
- Sponsor
- Comanche Biopharma
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing CBP-4888 with Placebo (2 arms). Primary endpoints: Adverse Events at 30 days, Pain at Site of Injection at 30 days and 3 more. Started May 2023; status: completed.
02
Drugs
CBP-4888
Beyond the preview
Go deeper on NCT05881993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05881993.